Reve Technologies, Inc. (BSSP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2014 | 250.18 Thousand USD | 116.76% |
| 2013 | 115.42 Thousand USD | 478.84% |
| 2012 | 19.94 Thousand USD | -73.81% |
| 2011 | 76.12 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2015 Q3 | 377.55 Thousand USD | -1.4% |
| 2015 Q1 | 330.1 Thousand USD | 31.95% |
| 2015 Q2 | 382.92 Thousand USD | 16.0% |
| 2014 Q2 | 200 Thousand USD | 33.25% |
| 2014 Q4 | 250.18 Thousand USD | 16.35% |
| 2014 Q3 | 215.02 Thousand USD | 7.51% |
| 2014 Q1 | 150.1 Thousand USD | 30.05% |
| 2014 FY | 250.18 Thousand USD | 116.76% |
| 2013 Q3 | 9956.00 USD | -52.74% |
| 2013 FY | 115.42 Thousand USD | 478.84% |
| 2013 Q4 | 115.42 Thousand USD | 1059.31% |
| 2013 Q2 | 21.06 Thousand USD | 0.0% |
| 2013 Q1 | 21.06 Thousand USD | 5.64% |
| 2012 FY | 19.94 Thousand USD | -73.81% |
| 2012 Q1 | 86.26 Thousand USD | 13.31% |
| 2012 Q2 | 96.22 Thousand USD | 11.55% |
| 2012 Q3 | 104.57 Thousand USD | 8.68% |
| 2012 Q4 | 19.94 Thousand USD | -80.93% |
| 2011 Q4 | 76.12 Thousand USD | 15.12% |
| 2011 Q3 | 66.12 Thousand USD | 43.36% |
| 2011 Q2 | 46.12 Thousand USD | 0.0% |
| 2011 FY | 76.12 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.393% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 93.931% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.089% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.423% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.16% |
| Mesoblast Limited | 118.7 Million USD | 99.789% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 73.617% |
| Genus plc | 233.1 Million USD | 99.893% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 91.462% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 81.38% |
| Marizyme, Inc. | 18.71 Million USD | 98.663% |
| ContraFect Corporation | 2.88 Million USD | 91.316% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 66.642% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -84.654% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 82.702% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 89.244% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 95.579% |
| MultiCell Technologies, Inc. | 202.58 USD | -123397.877% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.565% |
| EV Biologics, Inc. | 1.49 Million USD | 83.263% |
| Q BioMed Inc. | 4.1 Million USD | 93.913% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.244% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 60.293% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 79.633% |
| Biomind Labs Inc. | 735.54 Thousand USD | 65.987% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.854% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.075% |
| Skye Bioscience, Inc. | 4.61 Million USD | 94.579% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 71.828% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -76.785% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 95.739% |
| IMV Inc. | 28.88 Million USD | 99.134% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -872.752% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 88.922% |
| GB Sciences, Inc. | 1.75 Million USD | 85.78% |
| Alpha Cognition Inc. | 1.22 Million USD | 79.5% |
| HST Global, Inc. | 98.31 Thousand USD | -154.459% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Halberd Corporation | 150 Thousand USD | -66.788% |
| Enzolytics Inc. | 996.33 Thousand USD | 74.89% |
| Resverlogix Corp. | 6.49 Million USD | 96.146% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 47.606% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 2.117% |
| argenx SE | 20 Million USD | 98.749% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.451% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 90.764% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -2346.768% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.94% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -24.707% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 89.566% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -9.111% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.63% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 91.733% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 30.449% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.769% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -68.298% |
| BioStem Technologies, Inc. | 4.71 Million USD | 94.69% |
| ONE Bio Corp. | 19.71 Million USD | 98.731% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -0.588% |
| Agentix Corp. | 50 Thousand USD | -400.364% |
| LadRx Corporation | 33.6 Thousand USD | -644.456% |
| Cell Source, Inc. | 9.25 Million USD | 97.297% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 66.916% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 66.916% |
| NovAccess Global Inc. | 2.19 Million USD | 88.627% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 96.463% |
| Itoco Inc. | 228.37 Thousand USD | -9.548% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -18.584% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 94.979% |
| Kadimastem Ltd | 891.22 Thousand USD | 71.928% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 37.742% |
| CytoDyn Inc. | 30.07 Million USD | 99.168% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 48.34% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 28.895% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 96.801% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -104.23% |
| Rebus Holdings, Inc. | 310 Thousand USD | 19.296% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 94.717% |
| International Stem Cell Corporation | 4.17 Million USD | 94.012% |
| Bioxytran, Inc. | 1.92 Million USD | 87.004% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -300.849% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 88.528% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 96.992% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 97.086% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 83.916% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 6.649% |
| Neutra Corp. | 54.15 Thousand USD | -361.965% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 86.329% |
| PureTech Health plc | 25.51 Million USD | 99.019% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 79.564% |
| IXICO plc | 472.02 Thousand USD | 46.998% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.386% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.598% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Cellectis S.A. | 92.77 Million USD | 99.73% |